The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...

AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impactAmsterdam, the Netherlands ? Royal Philips , a global ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 ...

The drop in GPM is likely due to the increasing proportion of sales from Leqembi, one of Eisai’s products. The company’s guidance for current-year sales of ¥790 billion, which is the same as last year ...

One of the Houston region’s best-known scientists and an outstanding communicator, Dr. Paul Schulz, will headline the annual ...

Treatment with lecanemab infusion was safe and generally well-tolerated within an outpatient memory clinic setting, with few infusion-related reactions and a low number of withdrawals due to adverse ...

Leqembi, produced by Eisai and Biogen, is not a cure for Alzheimer’s but significantly slows down cognitive decline. It ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...